We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current RX market cap is 135.68M. The company's latest EPS is CAD 0.5406 and P/E is 21.00.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 21.42M | 22.33M | 28.62M | 27.93M | 31.59M |
| Operating Income | 5.66M | 5.29M | 8.61M | 7.26M | 8.06M |
| Net Income | 4.37M | 3.8M | 6.28M | 5.46M | 6.46M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 30.97M | 33.57M | 37.17M | 40.49M | 41.53M |
| Total Liabilities | 5.17M | 6.78M | 5.61M | 7.12M | 6.77M |
| Total Equity | 25.79M | 26.8M | 31.56M | 33.36M | 34.76M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | 4.77M | 6.89M | 4.68M | 4.95M | 5.05M |
| Investing | -1.69M | 3.39M | -4.84M | -10.79M | 884k |
| Financing | -6.39M | -3.37M | -2.08M | -4.37M | -5.79M |
| Market Cap | 135.68M |
| Price to Earnings Ratio | 21.00 |
| Price to Sales Ratio | 4.29 |
| Price to Cash Ratio | 16.99 |
| Price to Book Ratio | 3.9 |
| Dividend Yield | - |
| Shares Outstanding | 11.95M |
| Average Volume (1 week) | 2.89k |
| Average Volume (1 Month) | 3.01k |
| 52 Week Change | 25.83% |
| 52 Week High | 12.13 |
| 52 Week Low | 8.24 |
| Spread (Intraday) | 0.4 (3.54%) |
| Company Name | Biosyent Inc |
| Address |
2476 argentia road mississauga, ontario L5N 6M1 |
| Website | https://www.biosyent.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
